CORE--CLINICAL LABORATORY FACILITY

核心临床实验室(CCL)的总体目标是 提供资源，熟练的实验室技术，和专业的 适合监测和评估的实验室参数 新型细胞毒性和免疫调节性抗肿瘤药物的活性。 该装置提供了多种可靠的分析方法，具有很高的 质量控制级别，然后将分析后的数据提供给 研究调查员。 CCL为细胞毒的临床试验提供实验室支持 模式和试验都有药效学终点。此外， CCL支持需要评估多个参数的试验 从患者资格的专门测试到质量 对专门治疗方式的控制。这种多功能 从癌症中心进化而来，启动了联合免疫研究- 调节性和细胞毒性疗法。CCL扩大了其职能， 现提供适当的实验室专科临床相关资料 用于监测这些癌症治疗的新方法。 共享资源的主要用户是癌症中心成员，他们 需要对同行评审的研究项目提供支持，这些项目涉及 CCL中提供的专门分析方法。

The overall objective of the Core Clinical Laboratory (CCL) are to provide resources, skilled laboratory technology, and specialized laboratory parameters that are appropriate to monitor and assess the activity of new cytotoxic and immune modulating anti-neoplastic agents. The unit provides a variety of reliable assay methodologies with a high level of quality control, and then supplies the analyzed data to the study investigator. The CCL provides the laboratory support for clinical trials of cytotoxic modalities and trials have pharmacodynamic endpoints. In addition, the CCL supports trials the require assessment of multiple parameters ranging from specialized tests for patient eligibility to quality control of specialized therapeutic modalities. This multiple function evolved from cancer center initiated studies with combination immune- modulating and cytotoxic therapies. The CCL has broadened its function, now providing the appropriate laboratory specialized clinical correlates for the monitoring of these novel approaches to cancer treatment. The primary users of the shared resource are Cancer Center members who need support for their peer reviewed research projects which involved the specialized assays available in the CCL.